- Joined
- Oct 6, 2014
- Messages
- 1,424 (0.41/day)
System Name | octo1 |
---|---|
Processor | dual Xeon 2687W ES |
Motherboard | Supermicro |
Cooling | dual Noctua NH-D14 |
Memory | generic ECC reg |
Video Card(s) | 2 HD7950 |
Storage | generic |
Case | Rosewill Thor |
A new drug that I've been following for a couple years looks like it will finally enter Phase III clinical trials. It's designed as an antidepressant but works on a completely different pathway than other drugs so if approved it will be the first in its class. Unfortunately, P3 trials can take about 3 years since they are the most expensive and rigorous and as a result only about 1 in 5 drugs that are tested ever actually make it to market but things look good right now for Glyx-13
New drug might help treat spinal cord injuries w/out surgery. It doesn't seem to cause the axons of nerve cells to regrow through scar tissue but causes the few remaining functional neurons to send out more branches thus allowing them to have a greater effect.
The Chicago-area company says that in clinical proof-of-concept studies, GLYX-13 “was well-tolerated and demonstrated rapid, robust and sustained antidepressant effects.” The drug works by targeting NMDA receptors, which increase synaptic plasticity and correct irregularities in how neural cells communicate.
“Our company was established to develop therapeutics that precisely modulate the NMDA receptor to normalize and even enhance neuronal communication, thereby correcting the dysfunction that is at the root of many CNS disorders,” CEO Norbert Riedel said in a statement. He added that the proceeds will go toward addressing other CNS diseases and disorders.
New drug might help treat spinal cord injuries w/out surgery. It doesn't seem to cause the axons of nerve cells to regrow through scar tissue but causes the few remaining functional neurons to send out more branches thus allowing them to have a greater effect.
After spinal cord injury, axons try to cross the injury site and reconnect with other cells but are stymied by scarring that forms after the injury. Previous studies suggested their movements are blocked when the protein tyrosine phosphatase sigma (PTP sigma), an enzyme found in axons, interacts with chondroitin sulfate proteoglycans, a class of sugary proteins that fill the scars.
Dr. Lang and his colleagues designed a drug called ISP to block the enzyme and facilitate the drug’s entry into the brain and spinal cord. Injections of the drug under the skin of paralyzed rats near the injury site partially restored axon growth and improved movements and bladder functions.